Intellectual
Property +
Commercialisation

The SBRC – Nottingham has been established to accelerate the development of our understanding of how microbial metabolism can be tailored to economically generate chemical feedstocks sustainably from waste gases. From this fundamental science approach, the SBRC – Nottingham will develop new synthetic biology tools and resources to be utilised by industry as well as academia, globally.

The SBRC - Nottingham will work closely with the University of Nottingham’s Technology Transfer Office to identify, assess and protect IP as it arises. The objective is to ensure that, as far as possible, all IP that has exploitable value is identified and used appropriately to maximise research, environmental, societal and economic impact from the Research Councils’ funding that underpins the Centre.

The ambition of the SBRC - Nottingham is that the tools and resources it generates will be actively promoted to global audiences of academics and industrialists. The SBRC-Nottingham intends that, wherever practicable, any research tools it develops will be made widely available to industry through non-exclusive research and / or commercialisation licences. Patented technologies associated with the SBRC that are currently available through the University are listed below. They are available to companies either as commercial or research licences.

To discuss your licensing needs please contact Dr Alan Burbidge, SBRC-Nottingham Centre Manager: Alan.burbidge@nottingham.ac.uk


Patented
Technologies:

 

Patent title

Synthetic Operon Construction in Clostridia Allele Coupled Exchange (ACE)

WO 2009/101400

Description

An homologous recombination system that avoids the need for a heterologous reporter system and which enables large tracts of DNA to be inserted into a host bacterium such as Clostridium acetylbutylicum.

Academic Publication

Integration of DNA into bacterial chromosomes from plasmids without a counter-selection marker. John T. Heap, Muhammad Ehsaan, Clare M. Cooksley, Yen-Kuan Ng, Stephen T. Cartman, Klaus Winzer, and Nigel P. Minton* Nucleic Acids Res. (2012); 40(8): e59.

Expanding the repertoire of gene tools for precise manipulation of the Clostridium difficile genome: allelic exchange using pyrE alleles. Ng YK, Ehsaan M, Philip S, Collery MM, Janoir C, Collignon A, Cartman ST and Minton NP, (2013). PloS one. 8(2), e56051

Patent title

A negative / counter selection marker for use in clostridia: Cod A selectable marker

WO 2010/084349

Description

The cytosine deaminase gene (codA) of Escherichia coli as a heterologous counter-selection marker for genetic manipulation of wild-type C. difficile strains. CodA not only converts cytosine to uracil but also converts the innocuous pyrimidine analog 5-fluorocytosine (FC) into the highly toxic 5-fluorouracil (FU) leading to incorporation of fluorinated nucleotides into DNA and RNA. It is this latter activity which allows CodA to be an effective counter-selection marker.

Academic Publication

Precise manipulation of the Clostridium difficile chromosome reveals a lack of association between tcdC genotype and toxin production. Applied Environmental Microbiology 78: 4683–90 Cartman ST, Kelly ML, Heeg D, Heap JT, Minton NP (2012)


Patent title

Transposon delivery system for clostridia (vector) TraDis Transposon system

WO 2013/144653

Description

A plasmid-based transposon system in which Clostridial cells transformed with the plasmid results in cut and paste integration of the transposon into chromosomal DNA with a selectable marker. Loss of the plasmid in non-permissive conditions (using inducible promoters) prevents further transposition and facilitates selection of transposon-carrying colonies and the creation of transposon libraries. The patent facilitates TraDIS (Langridge et al. (2009) Genome Res. 19: 2308-2316.

Academic Publication

Patent title

Orthogonal bacterial expression system

WO 2013/144647

Description

An expression system exploiting Group 5 RNA polymerase sigma factors for example the TcdR Sigma factor from Clostridium difficile. Such factors are poorly recognised in bacteria lacking Group 5 RNA Polymerase. An example of an orthogonal construct would be TcdR operably linked to a promoter recognised by TcdR and a heterologous DNA sequence in a bacterial host lacking any Group 5 RNA Polymerase and as such give constitutive expression of any TcdR-promoter linked DNA sequence.

Academic Publication


Patent title

ClosTron

US 20110124109 (US-only patent)

Description

A type II intron system based on TargeTron which enables gene knock-outs through intron insertion in Clostridia

http://clostron.com/

Academic Publication

The ClosTron: A universal gene knock-out system for the genus Clostridium. Heap, J.T., Pennington, O.J., Cartman, S.T., Carter, G.P. and Minton, N.P., 2007. Journal of Microbiological Methods. 70(3), 452-464

The ClosTron: Mutagenesis in Clostridium refined and streamlined. Heap JT, Kuehne SA, Ehsaan M, Cartman ST, Cooksley CM, Scott JC, Minton NP. J Microbiol Methods. 2010 Jan;80(1):49-55.

 


Partners